{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:04:11Z","timestamp":1788318251758,"version":"build-2803163510"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022824","name":"Sanofi Italia","doi-asserted-by":"publisher","award":["Research to care"],"award-info":[{"award-number":["Research to care"]}],"id":[{"id":"10.13039\/100022824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente 2024 n\u00b02042, 5x1000 project 2017 UAUT 5\/19"],"award-info":[{"award-number":["Ricerca Corrente 2024 n\u00b02042, 5x1000 project 2017 UAUT 5\/19"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG #23438"],"award-info":[{"award-number":["IG #23438"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018857","name":"International Myeloma Society","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100018857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018866","name":"Paula and Rodger Riney Foundation","doi-asserted-by":"publisher","award":["Translational Research Award 2023"],"award-info":[{"award-number":["Translational Research Award 2023"]}],"id":[{"id":"10.13039\/100018866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Extracellular vesicles (EVs) are critical mediators of intercellular communication and contribute to cancer progression and immune regulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We characterized EVs isolated from bone marrow (BM) plasma harvested from healthy donors and patients affected by Multiple Myeloma (MM) by Nano Tracking Analysis and by flow cytometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      EVs from MM patients were significantly more abundant and enriched in CD138, supporting their partial origin from malignant plasma cells, with additional input from BM resident cells, including monocytes and NK cells. Phenotypic profiling revealed increased expression of immune checkpoint molecules HLA-G, PD-1, and PD-L1 on MM-derived EVs compared to healthy controls. Functionally, MM-EVs suppressed Staphylococcal enterotoxin B (SEB)-induced T cell activation, as evidenced by reduced IFN-\u03b3 production and CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cell proliferation. Such effects were partially reversed by HLA-G blockade. Moreover, MM-derived EVs modulated cytokine secretion profiles suppressing IL-2, IFN-\u03b1, TNF-\u03b1, and IL-6, and enhancing GM-CSF, with some changes attributed to HLA-G and PD-L1 activity. Transcriptomic analysis showed higher HLA-G expression in patients with gain of chromosome 1q, suggesting a link between high-risk cytogenetics and EV-driven immune suppression. While clinical correlations were not observed, likely due to limited sample size, these findings underscore the immunosuppressive role of MM-derived EVs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      HLA-G\n                      <jats:sup>+<\/jats:sup>\n                      , PD-1\n                      <jats:sup>+<\/jats:sup>\n                      , and PD-L1\n                      <jats:sup>+<\/jats:sup>\n                      EVs contribute to immune dysfunction in MM and represent promising targets to restore anti-tumor immunity.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1640168","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T04:13:53Z","timestamp":1756354433000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Bone marrow-derived extracellular vesicles from multiple myeloma patients promote adaptive immune dysfunction via HLA-G, PD-1, and PD-L1"],"prefix":"10.3389","volume":"16","author":[{"given":"Debora","family":"Soncini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Marimpietri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ladisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Airoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gramignoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Morandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/cancers12040924","article-title":"PD-L1-PD-1 pathway in the pathophysiology of multiple myeloma","volume":"12","author":"Tamura","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-416792","article-title":"CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis","volume":"120","author":"Brown","year":"2012","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2007.07.004","article-title":"Soluble HLA-G: Are they clinically relevant","volume":"17","author":"Pistoia","year":"2007","journal-title":"Semin Cancer Biol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1044-579X(03)00029-4","article-title":"HLA-G and lymphoproliferative disorders","volume":"13","author":"Amiot","year":"2003","journal-title":"Semin Cancer Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0456","article-title":"Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"11","author":"Leleu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/leu.2008.15","article-title":"NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G","volume":"22","author":"Maki","year":"2008","journal-title":"Leukemia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0993","article-title":"IL-18 induces PD-1-dependent immunosuppression in cancer","volume":"71","author":"Terme","year":"2011","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.coi.2015.01.006","article-title":"The evolution of checkpoint blockade as a cancer therapy: what's here, what's next","volume":"33","author":"Shin","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic Malignancy: preliminary results of a phase ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02749","article-title":"Promises and pitfalls in the use of PD-1\/PD-L1 inhibitors in multiple myeloma","volume":"9","author":"Oliva","year":"2018","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1279495","article-title":"Landscape of tumor and immune system cells-derived exosomes in lung cancer: mediators of antitumor immunity regulation","volume":"14","author":"Castillo-Pe\u00f1a","year":"2023","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11092534","article-title":"Communicator extraordinaire: extracellular vesicles in the tumor microenvironment are essential local and long-distance mediators of cancer metastasis","volume":"11","author":"Mitchell","year":"2023","journal-title":"Biomedicines"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119590","article-title":"Metastatic dissemination: role of tumor-derived extracellular vesicles and their use as clinical biomarkers","volume":"24","author":"Giusti","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1045624","article-title":"Tumor-derived extracellular vesicles modulate innate immune responses to affect tumor progression","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1458809","article-title":"Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD()","volume":"7","author":"Morandi","year":"2018","journal-title":"Oncoimmunology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00305","article-title":"Roles and modalities of ectonucleotidases in remodeling the multiple myeloma niche","volume":"8","author":"Chillemi","year":"2017","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/nyas.2015.1335.issue-1","article-title":"Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche","volume":"1335","author":"Quarona","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0036-9","article-title":"Extracellular vesicles in cancer - implications for future improvements in cancer care","volume":"15","author":"Xu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1265969","article-title":"Extracellular vesicles in hematological Malignancies: EV-dence for reshaping the tumoral microenvironment","volume":"14","author":"Van Morckhoven","year":"2023","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","article-title":"Extracellular vesicles as tools and targets in therapy for diseases","volume":"9","author":"Kumar","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"C29","DOI":"10.1152\/ajpcell.00280.2019","article-title":"Extracellular vesicles as biomarkers and therapeutic targets for cancer","volume":"318","author":"Urabe","year":"2020","journal-title":"Am J Physiol Cell Physiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1469771","article-title":"Immunomodulatory properties of extracellular vesicles isolated from bone marrow of patients with neuroblastoma: role of PD-L1 and HLA-G","volume":"15","author":"Marimpietri","year":"2024","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.909880","article-title":"Multiple myeloma-derived extracellular vesicles modulate the bone marrow immune microenvironment","volume":"13","author":"Lopes","year":"2022","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133236","article-title":"Extracellular vesicles enhance multiple myeloma metastatic dissemination","volume":"20","author":"Colombo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41408-018-0139-7","article-title":"Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts","volume":"8","author":"Faict","year":"2018","journal-title":"Blood Cancer J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225575","article-title":"Extracellular vesicles in multiple myeloma-cracking the code to a better understanding of the disease","volume":"14","author":"Iskrzak","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/febs.70093","article-title":"Extracellular vesicles in multiple myeloma: pathogenesis and therapeutic application","author":"Wylie","year":"2025","journal-title":"FEBS J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014749","article-title":"Exosomes in multiple myeloma: from bench to bedside","volume":"140","author":"Menu","year":"2022","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2015.09.061","article-title":"Merging colloidal nanoplasmonics and surface plasmon resonance spectroscopy for enhanced profiling of multiple myeloma-derived exosomes","volume":"77","author":"Di Noto","year":"2016","journal-title":"Biosens Bioelectron"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/cas.v116.7","article-title":"Immunosuppressive effects of multiple myeloma-derived extracellular vesicles through T cell exhaustion","volume":"116","author":"Hagiwara","year":"2025","journal-title":"Cancer Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119467","article-title":"Cross-dressing of multiple myeloma cells mediated by extracellular vesicles conveying MIC and ULBP ligands promotes NK cell killing","volume":"24","author":"Vulpis","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.791535","article-title":"HLA-G\/sHLA-G and HLA-G-bearing extracellular vesicles in cancers: potential role as biomarkers","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02046","article-title":"Soluble HLA-G and HLA-G bearing extracellular vesicles affect ILT-2 positive and ILT-2 negative CD8 T cells complementary","volume":"11","author":"Schwich","year":"2020","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1186\/s12885-015-2025-z","article-title":"Role of HLA-G and extracellular vesicles in renal cancer stem cell-induced inhibition of dendritic cell differentiation","volume":"15","author":"Grange","year":"2015","journal-title":"BMC Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1186\/s12967-024-05457-4","article-title":"Extracellular vesicles at the crossroad between cancer progression and immunotherapy: focus on dendritic cells","volume":"22","author":"Schioppa","year":"2024","journal-title":"J Transl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081106","article-title":"Vesicular-bound HLA-G as a predictive marker for disease progression in epithelial ovarian cancer","volume":"11","author":"Schwich","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2016.01.002","article-title":"The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients","volume":"77","author":"K\u00f6nig","year":"2016","journal-title":"Hum Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2025.01.001","article-title":"Esophageal squamous cell carcinoma derived sEV-PDL1 exhausts CD8(+)T cells to promote immunosuppression","volume":"178","author":"Li","year":"2025","journal-title":"Mol Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.18632\/aging.206020","article-title":"High expression of circulating exosomal PD-L1 contributes to immune escape of hepatocellular carcinoma and immune clearance of chronic hepatitis B","volume":"16","author":"Lin","year":"2024","journal-title":"Aging (Albany NY)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/s41419-021-03909-z","article-title":"Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer","volume":"12","author":"Signore","year":"2021","journal-title":"Cell Death Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/10815589231207801","article-title":"Integrin \u03b12 promotes immune escape in non-small-cell lung cancer by enhancing PD-L1 expression in exosomes to inhibit CD8 + T-cell activity","volume":"72","author":"Jing","year":"2024","journal-title":"J Investig Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1608582","DOI":"10.1155\/2024\/1608582","article-title":"Exosomal PDL1 suppresses the anticancer activity of CD8(+) T cells in hepatocellular carcinoma","volume":"2024","author":"Hu","year":"2024","journal-title":"Anal Cell Pathol (Amst)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa309","article-title":"EV PD-L1 is correlated with clinical features and contributes to T cell suppression in pediatric thyroid cancer","volume":"105","author":"Wang","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05259-6","article-title":"Clinical significance of plasma PD-L1(+) exosomes in the management of diffuse large B cell lymphoma","volume":"102","author":"Xu","year":"2023","journal-title":"Ann Hematol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12951-020-00710-6","article-title":"Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients","volume":"18","author":"Wang","year":"2020","journal-title":"J Nanobiotechnology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s00262-025-04047-7","article-title":"Exosomal PD-L1 derived from hypoxia nasopharyngeal carcinoma cell exacerbates CD8(+) T cell suppression by promoting PD-L1 upregulation in macrophages","volume":"74","author":"Yuan","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v12.15","article-title":"Prostate cancer cells synergistically defend against CD8(+) T cells by secreting exosomal PD-L1","volume":"12","author":"Li","year":"2023","journal-title":"Cancer Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3892\/or.2023.8525","article-title":"Exosomal PD\u2212L1 promotes the formation of an immunosuppressive microenvironment in gastric diffuse large B\u2212cell lymphoma","volume":"49","author":"Zeng","year":"2023","journal-title":"Oncol Rep"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2024.09.011","article-title":"Programmed death ligand-1 in melanoma and extracellular vesicles promotes local and regional immune suppression through M2-like macrophage polarization","volume":"195","author":"Huang","year":"2025","journal-title":"Am J Pathol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02491-9","article-title":"Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer","volume":"130","author":"Eslami","year":"2023","journal-title":"Br J Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12964-021-00816-w","article-title":"Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies","volume":"20","author":"Liu","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B59","doi-asserted-by":"publisher","first-page":"8995","DOI":"10.1039\/D2NR00829G","article-title":"Isolation of circulating exosomes and identification of exosomal PD-L1 for predicting immunotherapy response","volume":"14","author":"Zhang","year":"2022","journal-title":"Nanoscale"},{"key":"B60","doi-asserted-by":"publisher","first-page":"7830","DOI":"10.1038\/s41598-021-87575-3","article-title":"Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer","volume":"11","author":"Shimada","year":"2021","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001698","article-title":"Mechanisms underlying low-clinical responses to PD-1\/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1","volume":"9","author":"Yin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13046-022-02379-1","article-title":"Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer","volume":"41","author":"De Miguel-Perez","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-2220","article-title":"Tumor-derived small extracellular vesicles inhibit the efficacy of CAR T cells against solid tumors","volume":"83","author":"Zhong","year":"2023","journal-title":"Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12418","article-title":"PD-L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD-L1-low and -negative patients with non-small cell lung cancer","volume":"13","author":"Sch\u00f6ne","year":"2024","journal-title":"J Extracell Vesicles"},{"key":"B65","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s10020-024-00860-5","article-title":"The implication of serum HLA-G in angiogenesis of multiple myeloma","volume":"30","author":"Wang","year":"2024","journal-title":"Mol Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/cells11213365","article-title":"Extracellular vesicles isolated from plasma of multiple myeloma patients treated with daratumumab express CD38, PD-L1, and the complement inhibitory proteins CD55 and CD59","volume":"11","author":"Brennan","year":"2022","journal-title":"Cells"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.v193.3","article-title":"Molecular dynamics of targeting CD38 in multiple myeloma","volume":"193","author":"Malavasi","year":"2021","journal-title":"Br J Haematol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cytogfr.2016.07.005","article-title":"The untold story of IFN-\u03b3 in cancer biology","volume":"31","author":"Kursunel","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S347777","article-title":"Tumor-infiltrating PD-L1+ Neutrophils induced by GM-CSF suppress T cell function in laryngeal squamous cell carcinoma and predict unfavorable prognosis","volume":"15","author":"Tang","year":"2022","journal-title":"J Inflammation Res"},{"key":"B70","first-page":"589","article-title":"Oral squamous cell carcinoma cell-derived GM-CSF regulates PD-L1 expression in tumor-associated macrophages through the JAK2\/STAT3 signaling pathway","volume":"13","author":"Wang","year":"2023","journal-title":"Am J Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0268-960X(97)90019-9","article-title":"Role of alpha interferon in multiple myeloma","volume":"11","author":"Joshua","year":"1997","journal-title":"Blood Rev"},{"key":"B72","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1163462","article-title":"Role of IL-2 in cancer immunotherapy","volume":"5","author":"Jiang","year":"2016","journal-title":"Oncoimmunology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41577-022-00792-3","article-title":"Death by TNF: a road to inflammation","volume":"23","author":"Van Loo","year":"2023","journal-title":"Nat Rev Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1640168\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T04:13:54Z","timestamp":1756354434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1640168\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":74,"alternative-id":["10.3389\/fimmu.2025.1640168"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1640168","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"article-number":"1640168"}}